PATHOGENETIC ASPECTS OF ATHEROTHOMBOTIC RISK IN OBESITY AND THROMBOPHILIA
https://doi.org/10.17749/2070-4968.2015.9.3.045-052
Abstract
The assosiation between obesity, cardiovascular diseases and thrombosis is well-known and is caused by proinflammatory and prothombotic status in obesity. Numerous hormones and cytokines, secreted by adipocytes, influence the gene expression and function of endothelial cells, arterial smooth muscle cells, and monocytes leading to the development of an atherosclerotic plaque. Also, variety of cytokines produced by adipocytes controls endothelial function, hemostatic and fibrinolytic systems, platelet function, affecting progression of thombus formation. Nowadays,pathogenetic mechanisms of this relationship are under active study. Thrombophilia is another independent risk factor of tromboembolic complications.
About the Author
A. V. Khromylev
First Moscow State Medical Sechenov University
Russian Federation
graduate student of the Department of Obstetrics and Gynecology
Russian Federation
graduate student of the Department of Obstetrics and Gynecology
References
1. Makatsariya A.D., Bitsadze V.O. Antiphospholipid syndrome – the immune thrombophilia in obstetrics and gynecology [Antifosfolipidnyi sindrom – immunnaya trombofiliya v akusherstve i ginekologii (in Russian)]. Moscow. 2013; 485 s.
2. Makatsariya A.D., Beloborodova E.V., Baimuradova S.M., Bitsadze V.O. Gepergomotsisteinemiya and pregnancy complications [Gepergomotsisteinemiya i oslozhneniya beremennosti (in Russian)]. Moscow. 2007; 216 s.
3. Ageno W., Becattini C., Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008; 117: 93-102.
4. Aguilera C.M., Ramirez-Tortosa M.C., Mesa M.D., Gil A. Protective effect of monounsaturated and polyunsaturated fatty acids on the development of cardiovascular disease. Nutr Hosp. 2001; 16: 78-91.
5. Allman-Farinelli M.A. Obesity and venous thrombosis: a review. Semin Thromb Hemost. 2011; 37: 903-907.
6. Anfossi G., Russo I., Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009; 19: 440-449.
7. Aubert H., Frere C., Aillaud M.F. et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost. 2003; 1: 791-797.
8. Badimon L., Hernandez Vera R., Vilahur G. Atherothrombotic risk in obesity. Hamostaseologie. 2013; 33: 259-68.
9. Badimon L., Storey R.F., Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost. 2011; 105 (1): 34-42.
10. Badimon L., Vilahur G. Coronary atherothrombotic disease: progress in antiplatelet therapy. Rev Esp Cardiol. 2008; 61: 501-513.
11. Battinelli E.M., Bauer K.A. Thrombophilias in pregnancy. Hematol Oncol Clin North Am. 2011 Apr; 25 (2): 323-33.
12. Bavbek N., Kargili A., Kaftan О. et al. Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy? Clin Appl Thromb Hemost. 2007; 13: 391-397.
13. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008; 37: 635-646.
14. Corsonello A., Perticone F., Malara A. et al. Leptin- dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord. 2003; 27: 566-573.
15. Davi G., Guagnano M.T., Ciabattoni G. et al. Platelet activation in obese women: role of inflammation' and oxidant stress. JAMA. 2002; 288: 2008-2014.
16. De Ferranti S., Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008; 54: 945-955.
17. De Pergola G., Pannacciulli N., Coviello M. et al. sP- selectin plasma levels in obesity: association with insulin resistance and related metabolic and pro- thrombotic factors. Nutr Metab Cardiovasc Dis. 2008; 18: 227-232.
18. Eichinger S., Hron G., Bialonczyk С. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008; 168: 1678-1683.
19. Faber D.R., de Groot P.G., Visseren F.L. Role of adpose tissue in haemostasis, coagulation and fibrnolysis. Obes Rev. 2009; 10: 554-563.
20. Furie B., Furie B.C. Mechanisms of thrombus formation. N Engl J Med. 2008; 359: 938-949.
21. Gaspsyryan A.Y., Ayvazyan L., Mikhailidis D.P., Kitas G.D. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011; 17: 47-58.
22. Goralski K.B., Sinai C.J. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can J Physiol Pharmacol. 2007; 85: 113-132.
23. Gregor M.F., Hotamisligil G.S. Thematic review series: Adipocyte Biology. Adipocyte stress: the en doplasmic; reticulum and metabolic disease. J .Lipid Res. 2007; 48: 1905-1914.
24. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008; 29: 2959-2971.
25. Hernandez Vera R., Vilahur G., Badimon L. Obe sity with insulin resistance increase thrombosis in wild-type and bone marrow-transplanted Zucker fatty rats. Thromb Haemost. 2013; 109: 319-327.
26. Hernandez Vera R., Vilahur G., Ferrer-Lorente R. et al. Platelets derived from the bone marrow of diabetic animals show deregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis. Arterioscler Thromb Vase Biol. 2012; 32: 2141-2148.
27. Ibanez B., Vilahur G., Badimon J.J. Plaque progression and regression in atherothrombosis. J Thromb Haemost. 2007; 5 (1): 292-299.
28. James A.H. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009; 29: 326-331.
29. Kato H., Kashiwagi H., Shiraga M. et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vase Biol. 2006; 26: 224-230.
30. Kopp C.W., Kopp H.P., Steiner S. et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003; 11: 950-956.
31. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317-325.
32. Lijnen H., Collen D. Molecular and cellular basis of fibrinolysis. In: Hoffman R. Benz E.J., Shattil S.J., Furie В. et al. (eds). Elsevier: Philadelphia. 2005.
33. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007; 117: 175-184.
34. Mattu H.S., Randeva H.S. The role of adipokines in cardiovascular disease. J Endocrinol. 2013; 216: 17-3.
35. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314:1-16.
36. Meade T.W., Ruddock V., Stirling Y. et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993; 342: 1076-1079.
37. Molins В., Pena E., de la Torre R., Badimon L. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res. 2011; 92: 328-337.
38. Mottillo S., Filion K.B., Genest J. et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Am Coll Cardiol. 2010; 56: 1113-1132.
39. Murakami T., Horigome H., Tanaka K. et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res. 2007; 119: 45-53.
40. Nagai N., Hoylaerts M.F., Cleuren A.C. et al. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb Res. 2008; 122: 549-555.
41. Napoleone E., Ai D.I., Amore С et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possibledink between obesity and cardiovascular risk? J Thromb Haemost. 2007; 5: 1462-1468.
42. Natal C., Restituto P., Inigo С. et al. The proinflam- matory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponec- tin. J Clin Endocrinol Metab. 2008; 93: 2319-2327.
43. Poirier P., Giles T.D., Bray G.A. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006; 113: 898-918.
44. Rega G., Kaun C., Weiss T.W. et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation. 2005; 111: 1938-1945.
45. Rega-Kaun G., Kaun C., Wojta J. More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost. 2013; 110. DOI:10.1160/TH13-03-0212.
46. Russo I., Traversa M., Bonomo K. et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity. 2010; 18:788-797.
47. Samad F., Pandey M., de Waard V., Loskutoff D. Elevated PAI-1 and tissue factor gene expression in obese mice: a possible mechanism for the increased risk for cardiovascular disease associated with obesity. Fibrinol Proteol. 1997; 11: 17.
48. Steffen L.M., Cushman M., Peacock J.M. et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost. 2009; 7: 746-751.
49. Targher G., Zoppini G., Moghetti P., Day C.P. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost. 2010; 36: 41-48.
50. Xie H., Sheng L., Zhou H., Yan J. The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity. Br J Haematol. 2013 Oct 8. DOI: 10.1111/bjh.12587. [Epub ahead of print].
Review
For citations:
Khromylev A.V. PATHOGENETIC ASPECTS OF ATHEROTHOMBOTIC RISK IN OBESITY AND THROMBOPHILIA. Obstetrics, Gynecology and Reproduction. 2015;9(3):45-52. (In Russ.) https://doi.org/10.17749/2070-4968.2015.9.3.045-052
Views: 512
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
